Researchers identify signatures that predict how a person will respond to an immune system stimulus.

Death rates among blood cancer patients who contract COVID-19 are higher than for those with other cancers, pointing to impaired immunity that makes it hard to overcome the virus.

Half a year after infection, people who had recovered from COVID-19 had robust antibodies, along with traces of the virus in their gut, which may drive long-lasting immunity.

Outcomes in COVID-19 patients may be better in those recently infected with endemic coronaviruses. 

Discover how researchers are using flow cytometry to delve into the inner workings of the immune life cycle!

Experts will discuss their research on SARS-CoV-2 antibody persistence and immune memory in recovered COVID-19 patients and the implications for protective immunity.

An absence of germinal centers—which arise during infections to produce long-lived antibody-generating cells—might explain rapidly waning antibody levels in the disease.

A B-cell receptor critical for the production of a subset of intestinal antibodies has been pinpointed, but the function of those antibodies remains unclear.

Scientists are examining the role of T cells, which are likely crucial for long-term protection against SARS-CoV-2.